Status:
RECRUITING
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Lead Sponsor:
Janssen Research & Development, LLC
Conditions:
Geographic Atrophy
Macular Degeneration
Eligibility:
All Genders
60+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.
Eligibility Criteria
Inclusion
- Participants who were enrolled and received treatment with JNJ-81201887 or sham in a parent clinical study (81201887MDG2001, 81201887MDG1003)
- Females (women of childbearing potential), male participants, and partners of male participants will not be required to use contraception in this LTE study
- Must sign an informed consent form (ICF) indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study. The ICF may be signed by an impartial witness and/or legally designated representative depending on national/local regulations
Exclusion
- There are no exclusion criteria for this LTE study
Key Trial Info
Start Date :
September 19 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 16 2030
Estimated Enrollment :
274 Patients enrolled
Trial Details
Trial ID
NCT06635148
Start Date
September 19 2024
End Date
July 16 2030
Last Update
March 13 2026
Active Locations (104)
Enter a location and click search to find clinical trials sorted by distance.
1
Retina Associates Southwest PC
Tucson, Arizona, United States, 85704
2
Retina Consultants of Orange County
Fullerton, California, United States, 92835
3
Shiley Eye Institute Jacobs Retina Center
La Jolla, California, United States, 92093 0946
4
California Retina Consultants
Oxnard, California, United States, 93036